Order Article Reprints

Nishii Y, Furuhashi K, Ito K, Sakaguchi T, Suzuki Y, Fujiwara K, Yasuma T, Kobayashi T, D’Alessandro-Gabazza CN, Gabazza EC, et al. Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report. Pharmaceuticals. 2022; 15(7):889. https://doi.org/10.3390/ph15070889

Nishii, Yoichi, Kazuki Furuhashi, Kentaro Ito, Tadashi Sakaguchi, Yuta Suzuki, Kentaro Fujiwara, Taro Yasuma, Tetsu Kobayashi, Corina N. D’Alessandro-Gabazza, Esteban C. Gabazza, and et al. 2022. "Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report" Pharmaceuticals 15, no. 7: 889. https://doi.org/10.3390/ph15070889

Nishii, Y., Furuhashi, K., Ito, K., Sakaguchi, T., Suzuki, Y., Fujiwara, K., Yasuma, T., Kobayashi, T., D’Alessandro-Gabazza, C. N., Gabazza, E. C., Taguchi, O., & Hataji, O. (2022). Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report. Pharmaceuticals, 15(7), 889. https://doi.org/10.3390/ph15070889